{"id":1360,"date":"2026-04-06T15:00:00","date_gmt":"2026-04-06T15:00:00","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=1360"},"modified":"2026-04-06T19:32:30","modified_gmt":"2026-04-06T19:32:30","slug":"semax-peptide-neurotrophic-research-guide","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/semax-peptide-neurotrophic-research-guide\/","title":{"rendered":"Semax Peptide: Neurotrophic Research, Cognitive Studies &#038; Laboratory Applications"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/semax-peptide-neurotrophic-research-guide\/#Semax_Peptide_Neurotrophic_Research_Cognitive_Studies_Laboratory_Applications\" >Semax Peptide: Neurotrophic Research, Cognitive Studies &#038; Laboratory Applications<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/semax-peptide-neurotrophic-research-guide\/#What_Is_Semax\" >What Is Semax?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lotilabs.com\/resources\/semax-peptide-neurotrophic-research-guide\/#Development_Story\" >Development Story<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/semax-peptide-neurotrophic-research-guide\/#Chemistry_and_Structure\" >Chemistry and Structure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/semax-peptide-neurotrophic-research-guide\/#Mechanism_of_Action_BDNF_Is_the_Headline_But_Not_the_Whole_Story\" >Mechanism of Action: BDNF Is the Headline, But Not the Whole Story<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/semax-peptide-neurotrophic-research-guide\/#Preclinical_Findings_Stroke_Cognition_and_Gene_Expression\" >Preclinical Findings: Stroke, Cognition, and Gene Expression<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/lotilabs.com\/resources\/semax-peptide-neurotrophic-research-guide\/#Semax_vs_Selank_Same_Lab_Different_Compounds\" >Semax vs. Selank: Same Lab, Different Compounds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lotilabs.com\/resources\/semax-peptide-neurotrophic-research-guide\/#Safety_Profile\" >Safety Profile<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/lotilabs.com\/resources\/semax-peptide-neurotrophic-research-guide\/#Regulatory_Status\" >Regulatory Status<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/lotilabs.com\/resources\/semax-peptide-neurotrophic-research-guide\/#Research_Availability\" >Research Availability<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/lotilabs.com\/resources\/semax-peptide-neurotrophic-research-guide\/#Conclusion\" >Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/lotilabs.com\/resources\/semax-peptide-neurotrophic-research-guide\/#References\" >References<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Semax_Peptide_Neurotrophic_Research_Cognitive_Studies_Laboratory_Applications\"><\/span>Semax Peptide: Neurotrophic Research, Cognitive Studies &#038; Laboratory Applications<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p><em>For laboratory and research use only. Not for human consumption.<\/em><\/p>\n\n<p>One intranasal dose. 50 \u03bcg\/kg. That&#8217;s all it took. Within hours, BDNF mRNA in the hippocampus tripled. TrkB phosphorylation climbed 1.6-fold. A single administration.<\/p>\n\n<p>Data like that is why <a href=\"https:\/\/lotilabs.com\/product\/semax-5mg\/\">Semax<\/a> went from a niche Russian neuropeptide to one of the most studied nootropic compounds in neuroscience research. It&#8217;s a seven-amino-acid synthetic peptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4\u201310) fragment. The Pro-Gly-Pro tail bolted onto the C-terminus makes it resistant to enzymatic chewing \u2014 and, it turns out, carries independent pharmacological activity of its own. Three-plus decades in research. Registered in Russia since 1996. Preclinical data covering BDNF, NGF, dopamine, serotonin, stroke neuroprotection, and immune signaling. That list sounds implausible for one peptide. Then you read the published papers and realize every pathway has data behind it.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Semax\"><\/span>What Is Semax?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Seven amino acids. MEHFPGP. A synthetic analogue of the ACTH(4\u201310) fragment \u2014 that&#8217;s the stretch of adrenocorticotropic hormone between residues 4 and 10 that carries the CNS activity. The full ACTH molecule stimulates cortisol release. Semax doesn&#8217;t. Zero hormonal activity. All the brain effects, none of the adrenal stimulation.<\/p>\n\n<ul>\n<li><strong>Sequence:<\/strong> Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)<\/li>\n<li><strong>Classification:<\/strong> Synthetic ACTH(4\u201310) analogue with PGP extension<\/li>\n<li><strong>Molecular Weight:<\/strong> ~813.97 g\/mol<\/li>\n<li><strong>Route (preclinical):<\/strong> Predominantly intranasal<\/li>\n<li><strong>Status:<\/strong> Investigational research compound; not FDA-approved<\/li>\n<\/ul>\n\n<p>The PGP tail isn&#8217;t just armor against peptidases. It has independent biological activity \u2014 immunomodulatory signaling and improved blood-brain barrier penetration after intranasal delivery. You&#8217;re looking at a bifunctional molecule: ACTH(4\u20137) activity paired with PGP-mediated effects (PMC11498467). Two pharmacological programs in one peptide.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Development_Story\"><\/span>Development Story<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>1980s. Nikolay Myasoedov&#8217;s lab at the Institute of Molecular Genetics, Russian Academy of Sciences. Same institute that produced <a href=\"https:\/\/lotilabs.com\/product\/selank-10mg\/\">Selank<\/a>. The goal: take the ACTH(4\u201310) fragment \u2014 already known to have CNS effects \u2014 and make it last long enough to be useful. Intranasal delivery. No hormonal baggage.<\/p>\n\n<p>They succeeded. By 1996, Semax was registered in the Russian Federation for post-stroke recovery, optic nerve atrophy, and cognitive impairment. It&#8217;s still available there and in Ukraine as a nasal spray. Three decades of published research, mostly in Russian-language journals \u2014 though international work is picking up as transcriptomic and proteomic tools make Semax&#8217;s multi-pathway effects easier to characterize at a molecular level.<\/p>\n\n<p>No FDA approval. No EMA approval. In the West, Semax remains strictly a research compound. That hasn&#8217;t slowed the accumulation of preclinical data.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Chemistry_and_Structure\"><\/span>Chemistry and Structure<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Start with ACTH&#8217;s core pharmacophore \u2014 the His-Phe sequence at positions 6-7 that drives melanocortin-related CNS activity. Semax modifies the surrounding residues (swapping Arg-Trp for Pro-Gly-Pro) so you keep the brain activity but eliminate adrenal stimulation. The Met-Glu N-terminus and the PGP C-terminus are what make Semax a distinct compound rather than just an ACTH fragment.<\/p>\n\n<p>That PGP tail warrants attention. Studies on PGP alone show it activates neurotrophin transcription in ischemic brain tissue (PMC11498467). So the C-terminal extension isn&#8217;t passive \u2014 it&#8217;s an active pharmacological component that contributes to Semax&#8217;s neuroprotective profile independently of the ACTH-derived core.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_BDNF_Is_the_Headline_But_Not_the_Whole_Story\"><\/span>Mechanism of Action: BDNF Is the Headline, But Not the Whole Story<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Semax&#8217;s nootropic effects run through multiple pathways. BDNF\/TrkB gets the most attention. Rightfully \u2014 the numbers are striking. But there&#8217;s more happening underneath.<\/p>\n\n<h3>BDNF and TrkB: The Core Pathway<\/h3>\n\n<p>The landmark data comes from a Brain Research paper (PMID: 16996037). Single intranasal dose, 50 \u03bcg\/kg, in rodents. Hippocampal effects:<\/p>\n\n<ul>\n<li><strong>1.4-fold<\/strong> increase in BDNF protein<\/li>\n<li><strong>1.6-fold<\/strong> increase in TrkB phosphorylation<\/li>\n<li><strong>3-fold<\/strong> increase in exon III BDNF mRNA<\/li>\n<li><strong>2-fold<\/strong> increase in TrkB mRNA<\/li>\n<\/ul>\n\n<p>One dose. Hours. That&#8217;s not a marginal effect \u2014 that&#8217;s a robust neurotrophic signal.<\/p>\n\n<p>Binding studies went further: tritium-labeled Semax binds specific sites in rat basal forebrain with a K<sub>D<\/sub> of 2.4 \u00b1 1.0 nM and B<sub>MAX<\/sub> of 33.5 \u00b1 7.9 fmol\/mg protein. Calcium-dependent. Reversible. That&#8217;s receptor-mediated binding, not nonspecific membrane interaction. And the BDNF response was region-specific \u2014 basal forebrain yes, cerebellum no. Targeted, not diffuse.<\/p>\n\n<h3>NGF and Neurotrophin-3<\/h3>\n\n<p>BDNF isn&#8217;t alone. In permanent middle cerebral artery occlusion (pMCAO) models, Semax upregulated NGF, NT-3, and their high-affinity receptors (TrkA, TrkB, TrkC). Timing and magnitude varied by brain region and how long since the ischemic event (PMC11498467). That broad neurotrophin-activating profile is unusual \u2014 most compounds in this space hit one pathway, maybe two. Semax hits the full set.<\/p>\n\n<h3>Dopamine and Serotonin<\/h3>\n\n<p>Eremin et al. (2005) documented that Semax increases striatal dopamine release and amplifies locomotor responses to d-amphetamine. Serotonergic modulation runs alongside. These monoamine effects feed directly into what behavioral testing measures as improved attention, motivation, and cognitive processing. BDNF sets the stage for neuroplasticity; dopamine and serotonin handle the real-time performance effects.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Preclinical_Findings_Stroke_Cognition_and_Gene_Expression\"><\/span>Preclinical Findings: Stroke, Cognition, and Gene Expression<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h3>Neuroprotection in Ischemia<\/h3>\n\n<p>This is some of the most compelling Semax data. Genome-wide expression profiling (Illumina RatRef-12 BeadChip) on cortical tissue from pMCAO rodents (PMC3987924):<\/p>\n\n<p>At 3 hours post-stroke, Semax shifted expression of genes controlling immune cell activity and migration. By 24 hours, immune-response genes accounted for <strong>over 50%<\/strong> of all expression changes. Immunoglobulin genes were the most heavily upregulated group \u2014 several showing the highest expression amplitude of any transcript affected. Vascular system and intracellular calcium genes also moved.<\/p>\n\n<p>A 2020 ischemia-reperfusion study confirmed the pattern from the protein side: Semax compensated for mRNA expression disruption during ischemia-reperfusion, suppressed inflammatory and cell-death processes, and activated recovery pathways at both transcriptome and protein levels. Not just gene expression changes \u2014 actual neuroprotective biology.<\/p>\n\n<h3>Cognitive Effects<\/h3>\n\n<p>Consistent results across multiple rodent behavioral paradigms. Semax enhances conditioned avoidance reactions and learning-dependent behaviors. Memory consolidation improves. Attention sharpens. These cognitive gains correlate with measured BDNF\/TrkB increases in the hippocampus \u2014 mechanism and behavioral outcome lining up.<\/p>\n\n<p>Resting-state fMRI work adds anatomical context: Semax produces measurable changes in default mode network architecture, specifically the medial frontal cortex subcomponent. You can see the compound&#8217;s effects on functional brain connectivity, not just isolated neurotransmitter measures.<\/p>\n\n<h3>Transcriptomic Depth<\/h3>\n\n<p>In the intact rat hippocampus (no ischemia, no pathology), Semax modulates genes involved in intracellular signaling: MAPK10, APP (amyloid precursor protein), fibronectin 1. This tells you something important \u2014 Semax isn&#8217;t only active under pathological conditions. It engages fundamental neuroplasticity and tissue homeostasis pathways in normal brain tissue too.<\/p>\n\n<p>For labs studying neuropeptide signaling in cognition, <a href=\"https:\/\/lotilabs.com\/resources\/delta-sleep-inducing-peptide-dsip-benefits-uses-and-dosage\/\">DSIP<\/a> and <a href=\"https:\/\/lotilabs.com\/resources\/the-benefits-of-pinealon-peptide-for-brain-and-longevity-research\/\">Pinealon<\/a> are relevant comparisons.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Semax_vs_Selank_Same_Lab_Different_Compounds\"><\/span>Semax vs. Selank: Same Lab, Different Compounds<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Both heptapeptides. Both from Myasoedov&#8217;s institute. Both share the PGP tail. But they do fundamentally different things.<\/p>\n\n<table>\n<thead>\n<tr>\n<th>Parameter<\/th>\n<th>Semax<\/th>\n<th>Selank<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Parent<\/strong><\/td>\n<td>ACTH(4\u201310)<\/td>\n<td>Tuftsin<\/td>\n<\/tr>\n<tr>\n<td><strong>Sequence<\/strong><\/td>\n<td>MEHFPGP<\/td>\n<td>TKPRPGP<\/td>\n<\/tr>\n<tr>\n<td><strong>Primary Profile<\/strong><\/td>\n<td>Nootropic, neurotrophic, neuroprotective<\/td>\n<td>Anxiolytic, immunomodulatory<\/td>\n<\/tr>\n<tr>\n<td><strong>Core Mechanism<\/strong><\/td>\n<td>BDNF\/NGF upregulation, DA\/5-HT modulation<\/td>\n<td>GABA<sub>A<\/sub> modulation, enkephalinase inhibition<\/td>\n<\/tr>\n<tr>\n<td><strong>BDNF Effect<\/strong><\/td>\n<td>Primary: 1.4\u00d7 protein, 3\u00d7 mRNA<\/td>\n<td>Secondary: moderate, state-dependent<\/td>\n<\/tr>\n<tr>\n<td><strong>Cognitive Effects<\/strong><\/td>\n<td>Pronounced \u2014 attention, memory, avoidance learning<\/td>\n<td>Moderate \u2014 mainly under stress conditions<\/td>\n<\/tr>\n<tr>\n<td><strong>Anxiolytic<\/strong><\/td>\n<td>Modest mood stabilization<\/td>\n<td>Strong \u2014 benzo-equivalent without sedation<\/td>\n<\/tr>\n<tr>\n<td><strong>Russia Approval<\/strong><\/td>\n<td>1996<\/td>\n<td>2009<\/td>\n<\/tr>\n<tr>\n<td><strong>Gene Expression<\/strong><\/td>\n<td>24 vascular genes, extensive immune modulation in ischemia<\/td>\n<td>45 neurotransmission genes in frontal cortex<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<p>Quick version: Semax is the cognition compound. <a href=\"https:\/\/lotilabs.com\/product\/selank-10mg\/\">Selank<\/a> is the anxiety compound. Both touch neurotrophins. Both modulate the immune system. But their primary research domains don&#8217;t overlap much. Some labs run them in combination \u2014 hypothesizing complementary effects on cognition under stress \u2014 though controlled data on combination protocols is still limited.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Safety_Profile\"><\/span>Safety Profile<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Across every published preclinical study \u2014 clean. No hormonal effects despite the ACTH heritage. Semax does not trigger corticosterone or cortisol release. At intranasal doses of 50\u2013250 \u03bcg\/kg in rodents, nothing concerning showed up.<\/p>\n\n<p>Protocol design notes:<\/p>\n\n<ul>\n<li>The ACTH parentage is misleading \u2014 hormonal activity was specifically engineered out. No adrenal stimulation<\/li>\n<li>Binding is calcium-dependent. Control for that in your in vitro work or you&#8217;ll get artifacts<\/li>\n<li>BDNF response is region-specific: basal forebrain and hippocampus respond strongly, cerebellum doesn&#8217;t budge. Sample your tissues accordingly<\/li>\n<li>PGP tail makes Semax resistant to aminopeptidases. That changes your PK modeling assumptions<\/li>\n<\/ul>\n\n<p>Procurement basics: demand third-party COAs, HPLC purity data, and mass spec confirmation. Peptide aggregation and impurity risks are real with any research peptide.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Regulatory_Status\"><\/span>Regulatory Status<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p><strong>Russia\/Ukraine:<\/strong> Registered. Available as nasal spray for post-stroke recovery, optic nerve atrophy, and cognitive impairment. One of the few peptides with actual regulatory approval for CNS indications anywhere.<\/p>\n\n<p><strong>United States:<\/strong> Not FDA-approved for any indication. Research compound only. Not a controlled substance.<\/p>\n\n<p><strong>EU\/International:<\/strong> Not EMA-approved. Classified as investigational.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Research_Availability\"><\/span>Research Availability<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p><a href=\"https:\/\/lotilabs.com\/product\/semax-5mg\/\">Semax 5mg<\/a> from Loti Labs \u2014 third-party verified purity, suitable for in vitro and in vivo work. Researchers doing comparative neuropeptide pharmacology should also consider <a href=\"https:\/\/lotilabs.com\/product\/selank-10mg\/\">Selank 10mg<\/a> for parallel or combination studies.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Three decades of data and counting. A single dose triples hippocampal BDNF mRNA. Genome-wide profiling shows immune-response gene activation comprising over half of all ischemia-affected transcripts. Region-specific neurotrophic effects verified by binding studies with nanomolar affinity. Cognitive enhancement documented across multiple behavioral paradigms.<\/p>\n\n<p>Semax isn&#8217;t a simple nootropic. It&#8217;s a multi-pathway neurotrophic compound \u2014 BDNF, NGF, NT-3, dopamine, serotonin, and immune modulation \u2014 that happens to also improve cognition. The receptor it binds to hasn&#8217;t been definitively identified yet (K<sub>D<\/sub> = 2.4 nM, but the molecular target remains unknown). Neurodegenerative disease models are largely unexplored. And combination protocols with Selank and other neuropeptides are barely off the ground.<\/p>\n\n<p>There&#8217;s a lot of open territory here. For neuroscience labs with the right tools, Semax is one of the more interesting compounds to put under the microscope.<\/p>\n\n<p><em>For laboratory and research use only. Not for human consumption.<\/em><\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"References\"><\/span>References<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<ol>\n<li>Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. <em>Brain Res.<\/em> 2006;1117(1):54-60. PMID: 16996037<\/li>\n<li>Dergunova LV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia. <em>BMC Genomics.<\/em> 2014;15:228. PMC3987924<\/li>\n<li>Filippenkov IB, et al. Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia\u2013Reperfusion in Rats. <em>Genes.<\/em> 2020. PMC7555804<\/li>\n<li>Dolotov OV, et al. Semax, an analogue of adrenocorticotropin (4\u201310), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. <em>J Neurochem.<\/em> 2006;97 Suppl 1:82-86.<\/li>\n<li>Eremin KO, et al. Semax, An ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in Rodents. <em>Neurochem Res.<\/em> 2005;30:1493-1500.<\/li>\n<li>Dolotov OV, et al. The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo. <em>Doklady Biol Sci.<\/em> 2004;399:478-481.<\/li>\n<li>Filippenkov IB, et al. Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4\u20137)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia\u2013Reperfusion. <em>Int J Mol Sci.<\/em> 2021.<\/li>\n<li>Agapova TY, et al. Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia. <em>Cell Mol Neurobiol.<\/em> 2009. PMC11498467<\/li>\n<li>Ashmarin IP, et al. A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). <em>Zh Vyssh Nerv Deiat.<\/em> 1997;47(2):420-430.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Research guide on Semax, an ACTH(4-10) analogue that triples hippocampal BDNF mRNA in a single dose. Covers neurotrophic mechanisms, cognitive research, and neuroprotection studies.<\/p>\n","protected":false},"author":1,"featured_media":1385,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-1360","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=1360"}],"version-history":[{"count":0,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1360\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media\/1385"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=1360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=1360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=1360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}